The association of miR34b/c and TP53 gene polymorphisms with Wilms tumor risk in Chinese children

Abstract Wilms tumor is the most common pediatric malignancy in the kidney. The miR34b/c is a downstream target gene of the transcription factor p53. The important role of TP53 mutations, the methylation of miR34b/c, and the interaction between these two molecules in tumorigenesis have been well documented. Due to the biological connection between p53 and miR34b/c, in the present study, we investigated the association between polymorphisms in these two molecules and Wilms tumor susceptibility through genotyping two important functional polymorphisms (miR34b/c rs4938723 T>C and TP53 rs1042522 C>G) in 183 cases and 603 controls. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) derived from the logistic regression analysis were used to assess the correlation of miR34b/c rs4938723 and TP53 rs1042522 polymorphisms with Wilms tumor risk. Our results indicated that the association of miR34b/c rs4938723 and TP53 rs1042522 polymorphisms with Wilms tumor susceptibility was not statistically significant. Stratified analysis by age, gender, and clinical stage, as well as combined effect analysis were also performed, yet, no significant association was found. In conclusion, our study indicated a lack of association between the two selected polymorphisms and Wilms tumor susceptibility. Our findings need to be verified in studies with larger sample size in the future.

[1]  Jing He,et al.  The association of RAN and RANBP2 gene polymerphisms with Wilms tumor risk in Chinese children , 2020, Journal of Cancer.

[2]  Shuai Jiang.  Special issue editorial: Recent progress of MicroRNA research in immunity. , 2019, Cancer letters.

[3]  Jian Zhang,et al.  Association between rs4938723 polymorphism and the risk of primary open‐angle glaucoma (POAG) in a Chinese population , 2019, Journal of cellular biochemistry.

[4]  Jing He,et al.  MYCN gene polymorphisms and Wilms tumor susceptibility in Chinese children , 2019, Journal of clinical laboratory analysis.

[5]  H. Xia,et al.  Association of miR-34b/c rs4938723 and TP53 Arg72Pro Polymorphisms with Neuroblastoma Susceptibility: Evidence from Seven Centers , 2019, Translational oncology.

[6]  V. Rotter,et al.  p53 balances between tissue hierarchy and anarchy , 2019, Journal of molecular cell biology.

[7]  J. Soh,et al.  Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma. , 2019, International journal of oncology.

[8]  N. Cho,et al.  p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy , 2019, British Journal of Cancer.

[9]  H. Xia,et al.  Association of KRAS and NRAS gene polymorphisms with Wilms tumor risk: a four-center case-control study , 2019, Aging.

[10]  J. Kurie,et al.  MiR-34a and miR-34b/c have distinct effects on the suppression of lung adenocarcinomas , 2019, Experimental & Molecular Medicine.

[11]  P. Liu,et al.  TP53 rs1042522 C>G polymorphism and Wilms tumor susceptibility in Chinese children: a four-center case–control study , 2019, Bioscience reports.

[12]  S. Ghavami,et al.  Association between miR‐34b/c rs4938723 polymorphism and risk of cancer: An updated meta‐analysis of 27 case‐control studies , 2018, Journal of cellular biochemistry.

[13]  P. Radice,et al.  Genetic and epigenetic analyses guided by high resolution whole-genome SNP array reveals a possible role of CHEK2 in Wilms tumour susceptibility , 2018, Oncotarget.

[14]  H. Xia,et al.  Base Excision Repair Gene Polymorphisms and Wilms Tumor Susceptibility , 2018, EBioMedicine.

[15]  N. Phuong,et al.  Methylation profiles of miR34 gene family in Vietnamese patients suffering from breast and lung cancers. , 2018, Molecular medicine reports.

[16]  D. Canning.  Re: Risk of Adverse Health and Social Outcomes up to 50 Years after Wilms Tumor: The British Childhood Cancer Survivor Study. , 2018, The Journal of urology.

[17]  H. Xia,et al.  Association of Common Genetic Variants in Pre-microRNAs and Neuroblastoma Susceptibility: A Two-Center Study in Chinese Children , 2018, Molecular therapy. Nucleic acids.

[18]  Ying Zhu,et al.  Exome-wide analyses identify low-frequency variant in CYP26B1 and additional coding variants associated with esophageal squamous cell carcinoma , 2018, Nature Genetics.

[19]  M. Hashemi,et al.  Association between Pri-miR-34b/c rs4938723 polymorphism and bladder cancer risk , 2017, Journal of biomedical research.

[20]  T. Cai,et al.  Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies , 2017, Scientific Reports.

[21]  Zhuorong Zhang,et al.  The TP53 gene rs1042522 C>G polymorphism and neuroblastoma risk in Chinese children , 2017, Aging.

[22]  H. Xia,et al.  Association between TP53 gene Arg72Pro polymorphism and Wilms' tumor risk in a Chinese population. , 2017, OncoTargets and therapy.

[23]  Jinhong Zhu,et al.  BARD1 Gene Polymorphisms Confer Nephroblastoma Susceptibility , 2017, EBioMedicine.

[24]  Xuejun Zhang,et al.  pri-miR-34b/c rs4938723 polymorphism is associated with hepatocellular carcinoma risk: a case-control study in a Chinese population. , 2017, International journal of molecular epidemiology and genetics.

[25]  Jiaoyuan Li,et al.  Genetic variants in the regulatory region of SLC10A1 are not associated with the risk of hepatitis B virus infection and clearance. , 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[26]  James R. Anderson,et al.  Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  H. Xia,et al.  Association of potentially functional variants in the XPG gene with neuroblastoma risk in a Chinese population , 2016, Journal of cellular and molecular medicine.

[28]  C. Shaw,et al.  Mutations in the transcriptional repressor REST predispose to Wilms tumor , 2015, Nature Genetics.

[29]  Shu Liu,et al.  Association of p53 rs1042522, MDM2 rs2279744, and p21 rs1801270 polymorphisms with retinoblastoma risk and invasion in a Chinese population , 2015, Scientific Reports.

[30]  V. Vaira,et al.  Deregulation of MiR-34b/Sox2 Predicts Prostate Cancer Progression , 2015, PloS one.

[31]  C. Peng,et al.  Association between miR34b/c Polymorphism rs4938723 and Cancer Risk: A Meta-Analysis of 11 Studies including 6169 Cases and 6337 Controls , 2014, Medical science monitor : international medical journal of experimental and clinical research.

[32]  S. Seal,et al.  Germline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour , 2014, Nature Communications.

[33]  C. Hother,et al.  Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another “double hit” lymphoma with very poor outcome? , 2013, Oncotarget.

[34]  E. Lerut,et al.  p53 Immunohistochemistry expression in Wilms tumor: a prognostic tool in the detection of tumor aggressiveness. , 2013, The Journal of urology.

[35]  H. Seuánez,et al.  WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor. , 2013, Oncology reports.

[36]  A. Ashworth,et al.  Molecular profiling reveals frequent gain of MYCN and anaplasia‐specific loss of 4q and 14q in wilms tumor , 2011, Genes, chromosomes & cancer.

[37]  D. Jin,et al.  Epigenetic inactivation of the MIR34B/C in multiple myeloma. , 2011, Blood.

[38]  Hongbing Shen,et al.  A potentially functional polymorphism in the promoter region of miR‐34b/c is associated with an increased risk for primary hepatocellular carcinoma , 2011, International journal of cancer.

[39]  M. Stratton,et al.  Constitutional translocation breakpoint mapping by genome-wide paired-end sequencing identifies HACE1 as a putative Wilms tumour susceptibility gene , 2009, Journal of Medical Genetics.

[40]  V. Huff,et al.  Wilms tumor genetics: Mutations in WT1, WTX, and CTNNB1 account for only about one‐third of tumors , 2008, Genes, chromosomes & cancer.

[41]  N. Nowak,et al.  Fine structure analysis of the WT1 gene in sporadic Wilms tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[42]  B. Williams,et al.  Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor. , 1994, Cancer research.

[43]  N. Lemoine,et al.  Aberrant expression of the tumour suppressor gene p53 is very frequent in Wilms' tumours , 1992, The Journal of pathology.